TERT and neoplasm: TERT promoter mutations were also associated with adverse outcomes including tumor persistence/recurrence (OR, 4.59; 95% CI, 2.08–10.13 P < 0.05) and disease-specific mortality (OR, 9.28; 95% CI, 3.35–25.70; P < 0.05).